The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
to my knowledge none of the companies that are doing this I may be incorrect on this by the way but the last time I looked which was about a year ago not a single company was correctly sequencing The epig genome on these things so they were not able to accurately say what they were giving you an average representation of your methylation but they weren't going base pair by base pair and actually sequencing this the way we would sequence The genome
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.